Acorda Therapeutics (NASDAQ:ACOR) Earns Buy Rating from Analysts at StockNews.com
StockNews.com started coverage on shares of Acorda Therapeutics (NASDAQ:ACOR – Free Report) in a research note released on Thursday morning. The brokerage issued a buy rating on the biopharmaceutical company’s stock. Acorda Therapeutics Stock Up 8.8 % Shares of NASDAQ ACOR opened at $14.80 on Thursday. Acorda Therapeutics has a 12-month low of $8.98 and […]
More Stories
Synovus Financial Corp. (NYSE:SNV) Sees Significant Decline in Short Interest
Synovus Financial Corp. (NYSE:SNV – Get Free Report) was the recipient of a significant drop in short interest during the...
Short Interest in P3 Health Partners Inc. (NASDAQ:PIII) Declines By 23.4%
P3 Health Partners Inc. (NASDAQ:PIII – Get Free Report) was the recipient of a large drop in short interest in...
Applied Materials (NASDAQ:AMAT) Announces Earnings Results, Beats Expectations By $0.13 EPS
Applied Materials (NASDAQ:AMAT – Get Free Report) issued its earnings results on Thursday. The manufacturing equipment provider reported $2.32 earnings...
Prenetics Global Limited (NASDAQ:PRE) Short Interest Update
Prenetics Global Limited (NASDAQ:PRE – Get Free Report) was the recipient of a large growth in short interest during the...
Short Interest in Option Care Health, Inc. (NASDAQ:OPCH) Drops By 24.7%
Option Care Health, Inc. (NASDAQ:OPCH – Get Free Report) saw a significant decrease in short interest in the month of...
Global X NASDAQ 100 Risk Managed Income ETF (NASDAQ:QRMI) Sees Large Increase in Short Interest
Global X NASDAQ 100 Risk Managed Income ETF (NASDAQ:QRMI – Get Free Report) was the recipient of a large increase...